Detalles de la búsqueda
1.
Pre-analytical stability of the CEA, CYFRA 21.1, NSE, CA125 and HE4 tumor markers.
Tumour Biol
; 46(s1): S15-S25, 2024.
Artículo
Inglés
| MEDLINE | ID: mdl-37302060
2.
An Automated Correction Algorithm (ALPACA) for ddPCR Data Using Adaptive Limit of Blank and Correction of False Positive Events Improves Specificity of Mutation Detection.
Clin Chem
; 67(7): 959-967, 2021 07 06.
Artículo
Inglés
| MEDLINE | ID: mdl-33842952
3.
A Micro-Costing Framework for Circulating Tumor DNA Testing in Dutch Clinical Practice.
J Mol Diagn
; 25(1): 36-45, 2023 01.
Artículo
Inglés
| MEDLINE | ID: mdl-36402278
4.
Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II-IIIA NSCLC patients.
Mol Oncol
; 16(14): 2719-2732, 2022 07.
Artículo
Inglés
| MEDLINE | ID: mdl-35674097
5.
Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guide tyrosine kinase inhibitor treatment decisions.
ERJ Open Res
; 5(1)2019 Feb.
Artículo
Inglés
| MEDLINE | ID: mdl-30918895
6.
A serum and platelet-rich plasma serotonin assay using liquid chromatography tandem mass spectrometry for monitoring of neuroendocrine tumor patients.
Clin Chim Acta
; 469: 130-135, 2017 Jun.
Artículo
Inglés
| MEDLINE | ID: mdl-28385629
7.
Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments.
Eur J Cancer
; 48(5): 662-71, 2012 Mar.
Artículo
Inglés
| MEDLINE | ID: mdl-21945100
Resultados
1 -
7
de 7
1
Próxima >
>>